Estimaciones de analistas de Wall Street para AnaptysBio, Inc. (ANAB): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 16 |
| Mantener | 6 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 22 |
| Calificación media (1-5) | 0.73 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-10 | $-0.05 | ||
| 2026-09-11 | $-0.47 | $-0.47 | +0.0% |
| 2026-05-12 | $-1.84 | $-0.32 | -475.0% |
| 2026-03-03 | $1.58 | $0.89 | +77.5% |
| 2025-11-04 | $0.52 | $-1.06 | +149.1% |
| 2025-08-07 | $-1.34 | $-1.50 | +10.7% |
| 2025-05-05 | $-1.28 | $-1.30 | +1.5% |
| 2025-02-27 | $-0.72 | $-1.55 | +53.5% |
Ratios de valoración
| Precio / Valor contable | 119.13 |
| EV / EBITDA | 28.42 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $16.7M | $10.0M | $5.0M | $8.0M | $75.0M | $63.2M | $10.3M | $17.2M | $91.3M | $234.6M |
| Coste de Ventas | $15.4M | $29.4M | $56.2M | $99.3M | $80.0M | $98.5M | $88.8M | $132.3M | $163.8M | $2.4M |
| Beneficio Bruto | $1.3M | -$19.4M | -$51.2M | -$91.3M | -$5.0M | -$35.3M | -$78.5M | -$115.1M | -$72.6M | $232.2M |
| I+D | $22.6M | $30.9M | $56.3M | $99.3M | $80.0M | $98.5M | $88.8M | $139.6M | $163.8M | $136.0M |
| Generales y Administrativos | $4.3M | $9.3M | $15.5M | $16.1M | $18.9M | $21.5M | $36.6M | $41.9M | $42.4M | $50.7M |
| Gastos Operativos | $4.3M | $9.3M | $15.5M | $16.1M | $18.9M | $21.5M | $36.6M | $49.3M | $42.4M | $184.3M |
| Beneficio Operativo | -$3.0M | -$28.8M | -$66.7M | -$107.4M | -$23.9M | -$56.8M | -$115.2M | -$164.4M | -$114.9M | $47.9M |
| EBITDA | -$3.6M | -$28.1M | -$59.9M | -$95.9M | -$19.4M | -$55.7M | -$105.3M | -$156.4M | -$92.7M | $69.2M |
| Gastos por Intereses | $458000 | $1.8M | $1.7M | $1.0M | 0 | $1.4M | $21.1M | $18.1M | $50.1M | $79.9M |
| Beneficio Antes de Impuestos | -$4.3M | -$30.1M | -$61.8M | -$97.5M | -$19.9M | -$57.8M | -$128.7M | -$163.6M | -$145.2M | -$13.1M |
| Impuestos | 0 | 0 | -$192000 | -$152000 | 0 | 0 | $24000 | -$4000 | $3000 | $164000 |
| Beneficio Neto | -$4.3M | -$30.1M | -$61.7M | -$97.3M | -$19.9M | -$57.8M | -$128.7M | -$163.6M | -$145.2M | -$13.2M |
| BPA | $-0.23 | $-1.52 | $-2.50 | $-3.60 | $-0.73 | $-2.11 | $-4.57 | $-6.08 | $-5.12 | $-0.46 |
| BPA Diluido | $-0.23 | $-1.52 | $-2.50 | $-3.60 | $-0.73 | $-2.11 | $-4.57 | $-6.08 | $-5.12 | $-0.46 |
| Acciones en Circulación (Diluidas) | $2.6M | $19.8M | $24.7M | $27.1M | $27.3M | $27.4M | $28.2M | $26.9M | $28.4M | $31.3M |
Precio
| Precio | $54.31 |
| Capitalización | $1.6B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: BBOT · DNTH · KOD · MNMD · NRIX · OCS · PHAT
Explorar sector: Healthcare · Biotechnology
Más secciones de ANAB: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones